Efficacy of Incobotulinum toxin‐A for the treatment of masseter muscle hypertrophy in Asian Indian patients: A 2‐year follow‐up study

• Published in: Journal of cosmetic dermatology Vol. 19; no. 8; pp. 1892 - 1899
• Main Authors: Shome, Debraj, Vadera, Sapna, Shiva Ram, Male, Kapoor, Rinky
• Format: Journal Article
• Language: English
• Published: England 01.08.2020
• Subjects: Botulinum Toxins, Type A - therapeutic use; Canada; Follow-Up Studies; Humans; Hypertrophy - drug therapy; incobotulinumtoxinA; Injections, Intramuscular; Masseter Muscle - abnormalities; masseter muscle hypertrophy; Neuromuscular Agents - therapeutic use; Xeomin; Canada; masseter muscle hypertrophy; Xeomin; incobotulinumtoxinA
• ISSN: 1473-2130; 1473-2165
• DOI: 10.1111/jocd.13552

Background With the changing trends, more and more patients are opting for nonsurgical or minimally invasive options for reshaping the face. Noninvasive treatments such as incobotulinumtoxinA (Xeomin Cosmetic®; Merz Pharma Canada Ltd., Burlington, ON, Canada) are a preferred modality for reducing the volume of the muscle and therefore reducing the width of masseter. Aims To evaluate the efficacy of Xeomin treatment in long‐term management of bilateral masseter hypertrophy in Asian Indian patients. Patients/Methods A total of 30 patients were enrolled in the study and were injected with 30 U Xeomin on each side of face, at baseline. Fifteen patients received a second session of Xeomin injection at 12th week, and remaining 15 patients received an additional third session, at 12th and 24th weeks post the first injection, respectively. Follow‐up was done at 4th‐, 12th‐, 24th‐, and 36th‐week and at first‐ and second‐year follow‐ups. Results For the patients who received two injections, the maximum reduction of 26.85% was observed at 24th week, which was maintained as 20.04% reduction until second follow‐up year. The patients who received three injections exhibited very high reduction of 43.12% of masseter volume at 36th week, which was maintained at 38.72 % until the second follow‐up year. Three sessions of Xeomin injections were proved to be more effective in long‐term maintenance of reduced masseter volume than 2 sessions of injections. Conclusions Xeomin injections were found to be effective in long‐term management of bilateral masseter hypertrophy. This is the first of its kind paper, which evaluates the long‐term effects of Xeomin injections for the treatment of masseter hypertrophy.